Neuraxpharm has signed an exclusive distribution agreement with Pendopharm®, a division of Pharmascience Inc., for the commercialization of Buccolam® (Midazolam hydrochloride oromucosal solution) in Canada.
Through our network of strategic partnerships around the world, Neuraxpharm is committed to expanding access to market-leading medicines. Our collaboration with Pendopharm further strengthens our position as a global CNS specialist enabling us to provide support to patients and their caregivers.